Results 71 to 80 of about 1,580 (184)

Evaluation of Percutaneous Intramyocardial Septal Pulsed Field Ablation in a Rabbit Model: Safety, Efficacy, and Feasibility

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background Percutaneous intramyocardial (PIM) septal pulsed field ablation (SPFA) represents an innovative technique for the management of hypertrophic obstructive cardiomyopathy. However, the paucity of pertinent animal models has impeded comprehensive investigation. This study aimed to assess the safety, efficacy, and feasibility of PIM‐SPFA, as well
Xing-an Zhao, Hua-lei Dai, Si-ming Tao, Yi-jian Zhang, Ji Jia, Li-juan Song, Man Yang, Yun-na Ge, Xi-ya Wang, Juan Qing, Piotr Musialek   +10 more
wiley   +1 more source

Pharmacological Inhibition of β Myosin II Disrupts Sarcomere Assembly in Human iPSC‐Derived Cardiac Myocytes

Cytoskeleton, Volume 82, Issue 12, Page 795-803, December 2025.
ABSTRACT Sarcomeres are the fundamental contractile units of striated muscle. The functional roles of the cardiac‐specific myosin heavy chains, MYH6 (α myosin II) and MYH7 (β myosin II) during sarcomere assembly remain controversial. To address this, we utilized a selective MYH7 inhibitor, mavacamten, in combination with siRNA‐mediated knockdown of ...
James B. Hayes, Dylan T. Burnette
wiley   +1 more source

Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in ...
Milind Y. Desai, Andrew Gaballa, Yuichiro Okushi, Mohammed Abusafia, Shada Jadam, Katy Rutkowski, Susan Ospina, Sanaa Sultana, Maran Thamilarasan, Craig Asher, Zoran B. Popovic, Bo Xu   +11 more
doaj   +1 more source

Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis With High Surgical Risk

JACC: Case Reports
Background: Treatment and accurate assessment of aortic valve stenosis (AS) with concomitant obstructive hypertrophic cardiomyopathy (HCM) prove challenging.
Omar M. Abdelfattah, MD, Robyn Bryde, MD, Kutaiba Nazif, MD, Matthew W. Martinez, MD   +3 more
doaj   +1 more source

Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: Clinical Trials and Future Challenges

Biomolecules
Hypertrophic cardiomyopathy (HCM) is a prevalent and often underdiagnosed genetic cardiac disorder characterized by left ventricular hypertrophy and, in many cases, dynamic left ventricular outflow tract obstruction (LVOTO).
Arnold Kukowka, Marek Droździk
doaj   +1 more source

Model‐Informed Recommendation of Mavacamten Posology for Chinese Adults With Obstructive Hypertrophic Cardiomyopathy

CPT: Pharmacometrics & Systems Pharmacology
Mavacamten is a cardiac myosin inhibitor for adults with obstructive hypertrophic cardiomyopathy (HCM). Dose optimization is performed 4 weeks after starting mavacamten, guided by periodic echo measurements of Valsalva left ventricular outflow tract ...
Xiaojie Wu, Shilpa Puli, Nanye Chen, Zhuang Tian, Peiwen Hsu, Jing Sun, Cheng Lyu, Samira Merali, Jing Zhang   +8 more
doaj   +1 more source

Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology

Biomedicines
Hypertrophic cardiomyopathy (HCM) is a heterogeneous group of heart muscle disorders that affects millions, with an incidence from 1 in 500 to 1 in 200. Factors such as genetics, age, gender, comorbidities, and environmental factors may contribute to the
Ewelina Młynarska, Ewa Radzioch, Bartłomiej Dąbek, Klaudia Leszto, Alicja Witkowska, Witold Czarnik, Weronika Jędraszak, Jacek Rysz, Beata Franczyk   +8 more
doaj   +1 more source

Mavacamten

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Pharmacogenetic testing to broaden patient eligibility for mavacamten

European Heart Journal - Cardiovascular Pharmacotherapy
The European Medicines Agency (EMA) approved mavacamten in June 2023 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).1,2 Clinical trials have demonstrated its efficacy in improving exercise capacity, reducing the left ventricular outflow tract (LVOT) gradient, and alleviating symptoms, and decreases the need for invasive
Lorenz Van der Linden, Lucas Van Aelst, Iacopo Olivotto   +2 more
openaire   +3 more sources

Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging.

PLoS ONE
BackgroundHypertrophic Cardiomyopathy (HCM) is a complex cardiac condition characterized by hypercontractility of cardiac muscle leading to a dynamic obstruction of left ventricular outlet tract (LVOT).
Rahul Vyas, Viraj Panchal, Shubhika Jain, Manush Sondhi, Mansunderbir Singh, Keerthish Jaisingh, Sahith Reddy Thotamgari, Anuj Thakre, Kalgi Modi   +8 more
doaj   +1 more source